Navigation Links
Auxogyn licenses noninvasive embryo assessment technology from Stanford University

MENLO PARK, Calif. October 4, 2010 Auxogyn, Inc., a privately held medical technology company focused on women's reproductive health, today announced that it acquired an exclusive license from Stanford University to develop a set of products that may allow medical practitioners in the field of assisted reproduction to significantly improve the effectiveness of in vitro fertilization (IVF) procedures.

The technology licensed from Stanford is described in a publication titled 'Non-invasive imaging of human embryos before embryonic genome activation predicts development to the blastocyst stage,' now appearing in the online edition of Nature Biotechnology. This landmark study demonstrated, for the first time, that human embryo fate is already determined at the four-cell stage of development. The article is authored by Professor Renee Reijo Pera, Dr. Connie Wong, Dr. Kevin Loewke, Dr. Nancy Bossert, Dr. Barry Behr, Dr. Christopher De Jonge and Dr. Thomas Baer and showed that measuring a unique set of non‑invasive imaging parameters by day 2 may allow an embryologist to predict the embryos that will reach the blastocyst (day 5) stage of development with a very high degree of accuracy.

"Blastocyst formation is a critical time point in human embryo development and provides more objective criteria for selecting which embryo(s) to transfer," said Lissa Goldenstein, president and chief executive officer of Auxogyn, Inc. "For years, researchers have searched for ways to predict the embryos most likely to reach the blastocyst stage in order to enable earlier transfer and ultimately improve live birth rates for in vitro fertilization procedures."

"Building on the technology licensed from Stanford, we are developing a product that assesses early embryo viability at the 4-cell stage. We believe that generating key clinical data assessments may enable embryologists to improve the effectiveness of in vitro fertilization (IVF) procedures while providing women experiencing infertility the highest quality of patient care," continued Ms. Goldenstein.


Contact: Angela Bitting
AB Corporate Communications

Related biology news :

1. Brown licenses potential muscular dystrophy treatment to Tivorsan Pharmaceuticals
2. U of M licenses unique plant protection product
3. UC Riverside licenses technology to OlFactor Laboratories, Inc.
4. UT-Battelle licenses tissue regeneration technologies to NellOne Therapeutics, Inc.
5. Virginia Tech licenses GenoCAD source code to ISCB
6. TAXIS Pharmaceuticals licenses novel antimicrobial technology from Rutgers and UMDNJ
7. MSU licenses plant oil enhancement technology to BASF Plant Science
8. UGA licenses technology to make fuel from dead forests and agricultural waste
9. UGA licenses new Bermuda grass that thrives in sun and shade
10. UGA licenses invention that kills food-borne pathogens in minutes
11. Ocera Therapeutics licenses novel treatment for acute hepatic encephalopathy from UCLB
Post Your Comments:
(Date:6/7/2016)... 7, 2016  Syngrafii Inc. and San Antonio ... that includes integrating Syngrafii,s patented LongPen™ eSignature "Wet" ... collaboration will result in greater convenience for SACU ... while maintaining existing document workflow and compliance requirements. ... Highlights: ...
(Date:6/2/2016)...   The Weather Company , an IBM Business (NYSE: ... capability in which consumers will be able to interact with ... via voice or text and receive relevant information about the ... Marketers have long sought an advertising solution that can create ... relevant and valuable; and can scale across millions of interactions ...
(Date:5/24/2016)... May 24, 2016 Ampronix facilitates superior patient care by providing unparalleled technology ... LCD display is the latest premium product recently added to the range of products ... ... ... 3d Imaging- LCD Medical Display- Ampronix News ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... STACS DNA ... Technical Leader at the Arkansas State Crime Laboratory, has joined STACS DNA as a ... STACS DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. “In further ...
(Date:6/23/2016)... , June 23, 2016 Apellis ... Phase 1 clinical trials of its complement C3 ... single and multiple ascending dose studies designed to ... (PD) of subcutaneous injection in healthy adult volunteers. ... (SC) either as a single dose (ranging from ...
(Date:6/23/2016)... , June 23, 2016 ... Hematology Review, 2016;12(1):22-8 ... , the peer-reviewed journal from touchONCOLOGY, Andrew ... escalating cost of cancer care is placing an ... result of expensive biologic therapies. With the patents ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the only free ... and will showcase its product’s latest features from June 26 to June 30, ... poster on Disrupting Clinical Trials in The Cloud during the conference. DIA ...
Breaking Biology Technology: